Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study
Latest Information Update: 23 Dec 2025
At a glance
- Drugs SHR-1905 (Primary)
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 18 Dec 2025 Actual Primary Completion date changed to 3 Dec 2025.
- 18 Dec 2025 Status changed from active, no longer recruiting to completed.
- 25 Mar 2025 Status changed from recruiting to active, no longer recruiting.